Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 566 JPY 0.71%
Market Cap: 7.3T JPY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Takeda Pharmaceutical Co Ltd stock under the Base Case scenario is 6 498.35 JPY. Compared to the current market price of 4 566 JPY, Takeda Pharmaceutical Co Ltd is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
6 498.35 JPY
Undervaluation 30%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
52
vs Industry
59
Median 3Y
1.6
Median 5Y
1.6
Industry
2.4
Forward
1.6
More Details
34.8
P/E
P/E
Price to Earnings
34.8
vs History
33
vs Industry
13
Median 3Y
28.1
Median 5Y
28.5
Industry
20.5
Forward
52
More Details
6.5
P/OCF
P/OCF
Price to OCF
6.5
vs History
52
vs Industry
45
Median 3Y
6.8
Median 5Y
6.5
Industry
15.4
More Details
11.5
P/FCFE
P/FCFE
Price to FCFE
11.5
vs History
41
vs Industry
28
Median 3Y
11
Median 5Y
10.6
Industry
22.6
More Details
1
P/B
P/B
Price to Book Value
1
vs History
52
vs Industry
62
Median 3Y
0.9
Median 5Y
1
Industry
2
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
60
vs Industry
43
Median 3Y
2.5
Median 5Y
2.6
Industry
2.5
Forward
2.5
More Details
3.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.8
vs History
44
vs Industry
51
Median 3Y
3.7
Median 5Y
3.7
Industry
4.9
More Details
9.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.2
vs History
44
vs Industry
35
Median 3Y
8.9
Median 5Y
9
Industry
12.6
Forward
9.5
More Details
23.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.7
vs History
41
vs Industry
19
Median 3Y
22.2
Median 5Y
23.1
Industry
15.6
Forward
49.8
More Details
10.2
EV/OCF
EV/OCF
Enterprise Value to OCF
10.2
vs History
55
vs Industry
38
Median 3Y
10.6
Median 5Y
10.9
Industry
13.9
More Details
14.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.3
vs History
50
vs Industry
27
Median 3Y
13.9
Median 5Y
14.5
Industry
17.7
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
4
vs Industry
64
Median 3Y
0.8
Median 5Y
0.8
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Takeda Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
7.2T JPY 1.6 34.8 9.2 23.7
US
Eli Lilly and Co
NYSE:LLY
783.4B USD 17.4 74 43 47.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
389.2B USD 4.4 27.7 13 17
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.5 21.6 14.2 16.2
CH
Roche Holding AG
SIX:ROG
233.4B CHF 4 20.3 11.3 13.4
UK
AstraZeneca PLC
LSE:AZN
173.2B GBP 4.1 31.7 126.6 193.4
US
Merck & Co Inc
NYSE:MRK
223.1B USD 3.5 13 8.8 10.4
CH
Novartis AG
SIX:NOVN
196.7B CHF 4.3 18.6 11.3 14.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 2.2 17.8 8.5 12.1
P/E Multiple
Earnings Growth PEG
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
Average P/E: 28.8
34.8
22%
1.6
US
Eli Lilly and Co
NYSE:LLY
74
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.7
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
21.6
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.3
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
31.7
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
CH
Novartis AG
SIX:NOVN
18.6
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
Average EV/EBITDA: 396.3
9.2
2%
4.6
US
Eli Lilly and Co
NYSE:LLY
43
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.6
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
Average EV/EBIT: 1 701.9
23.7
5%
4.7
US
Eli Lilly and Co
NYSE:LLY
47.4
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
16%
1
CH
Roche Holding AG
SIX:ROG
13.4
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
CH
Novartis AG
SIX:NOVN
14.4
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.